首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   299813篇
  免费   17809篇
  国内免费   422篇
耳鼻咽喉   4272篇
儿科学   10367篇
妇产科学   10269篇
基础医学   45602篇
口腔科学   7586篇
临床医学   24412篇
内科学   56702篇
皮肤病学   6356篇
神经病学   21232篇
特种医学   11913篇
外国民族医学   43篇
外科学   47416篇
综合类   7771篇
现状与发展   1篇
一般理论   161篇
预防医学   20087篇
眼科学   6996篇
药学   21074篇
中国医学   791篇
肿瘤学   14993篇
  2019年   2290篇
  2018年   3683篇
  2017年   2714篇
  2016年   3156篇
  2015年   3566篇
  2014年   4686篇
  2013年   7325篇
  2012年   9252篇
  2011年   9689篇
  2010年   6262篇
  2009年   5655篇
  2008年   8831篇
  2007年   9715篇
  2006年   9571篇
  2005年   9160篇
  2004年   8872篇
  2003年   8325篇
  2002年   7960篇
  2001年   13475篇
  2000年   13821篇
  1999年   11584篇
  1998年   3057篇
  1997年   2829篇
  1996年   2658篇
  1995年   2574篇
  1994年   2373篇
  1992年   8414篇
  1991年   8540篇
  1990年   8355篇
  1989年   8156篇
  1988年   7393篇
  1987年   7147篇
  1986年   6782篇
  1985年   6577篇
  1984年   4818篇
  1983年   4156篇
  1982年   2487篇
  1979年   4463篇
  1978年   3245篇
  1977年   2759篇
  1976年   2515篇
  1975年   2855篇
  1974年   3367篇
  1973年   3373篇
  1972年   3136篇
  1971年   2959篇
  1970年   2852篇
  1969年   2597篇
  1968年   2550篇
  1967年   2381篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF.  相似文献   
3.

Objectives

To determine: (i) the behaviour change techniques used by a sample of Australian physiotherapists to promote non-treatment physical activity; and (ii) whether those behaviour change techniques are different to the techniques used to encourage adherence to rehabilitation exercises.

Design

Cross-sectional survey.

Method

An online self-report survey was advertised to private practice and outpatient physiotherapists treating patients with musculoskeletal conditions. The use of 50 behaviour change techniques were measured using five-point Likert-type scale questions.

Results

Four-hundred and eighty-six physiotherapists responded to the survey, with 216 surveys fully completed. Most respondents (85.1%) promoted non-treatment physical activity often or all of the time. Respondents frequently used 29 behaviour change techniques to promote non-treatment physical activity or encourage adherence to rehabilitation exercises. A similar number of behaviour change techniques was frequently used to encourage adherence to rehabilitation exercises (n = 28) and promote non-treatment physical activity (n = 26). Half of the behaviour change techniques included in the survey were frequently used for both promoting non-treatment physical activity and encouraging adherence to rehabilitation exercises (n = 25). Graded tasks was the most, and punishment was the least, frequently reported technique used to promote non-treatment physical activity and encourage adherence to rehabilitation exercises.

Conclusions

Respondents reported using similar behaviour change techniques to promote non-treatment physical activity and encourage adherence to rehabilitation exercises. The variability in behaviour change technique use suggests the behaviour the physiotherapist is promoting influences their behaviour change technique choice. Including the frequently-used behaviour change techniques in non-treatment physical activity promotion interventions might improve their efficacy.  相似文献   
4.
5.
6.
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号